Navigation Links
NIH awards Muscular Dystrophy Cooperative Research Center grants
Date:9/29/2010

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

The grants were awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Neurological Disorders and Stroke (NINDS) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for year one of five-year cooperative agreements.

The grants designate Nationwide Children's Hospital, Columbus, Ohio, as a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (MDCRC), and continue funding of crucial research by two previously established MDCRCs at the University of Pennsylvania, Philadelphia and the University of Iowa, Iowa City.

Researchers at Nationwide Children's Hospital, under the direction of Jerry Mendell, M.D., will further develop methods to overcome immune barriers to gene correction for Duchenne muscular dystrophy (DMD). A form of muscular dystrophy that affects children and young adults, DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Gene therapy for DMD includes injecting genes for a functional version of the muscle protein dystrophin, encased in a virus designed to deliver the gene into the muscle cells. In an early trial of this experimental therapy, blood analyses and biopsy slides showed that the immune system in more than half of the children mounted a response to dystrophin or the viral delivery vehicle.

The goal of the research will be to see how many patients have pre-existing immunity to dystrophin that could block the gene transfer. Researchers also will determine if the immune reaction could be circumvented by removing antibodies with a blood-purifying procedure called plasmapheresis or administering drugs that suppress the immune response.

At the University of Pennsylvania, researchers led by H. Lee Sweeney, Ph.D., will research treatments to inhibit muscle fibrosis, or scarring, that causes muscle dysfunction. By reducing scar formation, such treatments may not only improve muscle function, but may also enhance muscle regeneration and increase the effectiveness of drug, gene and stem cell therapies for muscular dystrophies (MD). The research aims to identify existing drugs that inhibit fibrosis, as well as drive the development of new classes of fibrosis inhibitors. The center's goal is to develop non-invasive imaging techniques to assess the replacement of skeletal and cardiac muscle with fat and scar tissue associated with MD progression.

Research at the University of Iowa, directed by Kevin Campbell, Ph.D., will explore therapeutic strategies for the treatment of various muscular dystrophies arising from the abnormal processing of muscle proteins called dystroglycans. This will involve investigating what happens on a molecular level in these dystrophies (called dystroglycanopathies) and evaluating various treatment strategies, using mouse models and cells with known mutations from dystroglycanopathy patients. It will also entail identifying and characterizing dystroglycanopathy patients and developing infrastructure for trials of dystroglycanopathy treatment in defined patient groups.

Muscular dystrophy is a group of debilitating, and often fatal, diseases characterized by progressive weakness and degeneration of the skeletal or voluntary muscles, which control movement and breathing. MD can affect people of all ages. Although some forms first become apparent in infancy or childhood, others may not appear until middle age or later.


'/>"/>

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
Source:Eurekalert

Related biology news :

1. NINDS awards new Udall Centers for Parkinsons Disease Research
2. Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards
3. MARC Travel Awards announced for the 2010 SACNAS Annual Meeting
4. MARC Travel Awards announced for the 2010 Biomedical Engineering Society Annual Meeting
5. MARC Travel Awards announced for the 2010 Society for Leukocyte Biology Meeting
6. MARC Travel Awards announced: The 2010 Società Italiana di Patologia XXX National Congress
7. Top cancer specialists receive ESMO awards
8. ORNL wins 2 awards for sustainability program
9. Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
10. Iowa State awards grants to develop health, energy and research technologies
11. NSF awards $10M to develop computing techniques for measuring and analyzing child behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... Feb. 23, 2017  In Atlanta, it seems everyone has ... culture intertwine to create an expressive and dynamic community unlike ... energy and contribute to it. With their ... Fairies seeks to carry on that tradition with a ... Atlanta salon is the newest of 13 nationwide ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
Breaking Biology Technology: